MD: University of Utah, Salt Lake City, UT, 2004.
Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 2008; Pediatric Hematology/Oncology, 2011.
Pediatric leukemia and lymphoma; investigation of the role of small Rho GTPases in leukemogenesis and leukemic stem cell biology and their potential as therapeutic targets in acute myeloid leukemia; development of xenograft models for use in testing novel therapeutics.
Cancer and Blood Diseases, Leukemia
Experimental Hematology and Cancer Biology, Oncology, Cancer and Blood Diseases
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.
Hegde, S; Gasilina, A; Wunderlich, M; Lin, Y; Buchholzer, M; Krumbach, OH F; Akbarzadeh, M; Ahmadian, MR; Seibel, W; Zheng, Y; et al.
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms.
Sabnis, HS; Shulman, DS; Mizukawa, B; Bouvier, N; Zehir, A; Fangusaro, J; Fabrizio, VA; Whitlow, C; Winchester, M; Agresta, L; et al.
Journal of Clinical Oncology.
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al.
Pediatric Blood and Cancer.
Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male.
Sabulski, A; Bartlett, AL; Koch, BL; Vatner, R; Mizukawa, B; Phillips, CL.
Journal of Pediatric Hematology/Oncology.
PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia.
Wunderlich, M; Manning, N; Sexton, C; O’Brien, E; Byerly, L; Stillwell, C; Perentesis, JP; Mulloy, JC; Mizukawa, B.
Frontiers in Oncology.
FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
Sheng, Y; Yu, C; Liu, Y; Hu, C; Ma, R; Lu, X; Ji, P; Chen, J; Mizukawa, B; Huang, Y; et al.
Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
He, X; Dou, A; Feng, S; Roman-Rivera, A; Hawkins, C; Lawley, L; Zhang, J; Wunderlich, M; Mizukawa, B; Halene, S; et al.
Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML.
Jones, LM; O'Brien, MM; Breese, EH; Absalon, M; Burns, KC; Grimley, M; Mizukawa, B; Lee, LH; Perentesis, JP; Phillips, CL.
Journal of Clinical Oncology.
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.
Hayashi, Y; Goyama, S; Liu, X; Tamura, M; Asada, S; Tanaka, Y; Fukuyama, T; Wunderlich, M; O'Brien, E; Mizukawa, B; et al.
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462
© 1999-2021 Cincinnati Children's Hospital Medical Center. All rights reserved.